{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:48:23Z","timestamp":1761824903824,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.advms.2023.05.001","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T22:52:18Z","timestamp":1684536738000},"page":"195-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interleukin-33\/sST2: Dynamic assessment in patients with acute coronary syndrome"],"prefix":"10.1016","volume":"68","author":[{"given":"Anna","family":"Witkowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9755-9761","authenticated-orcid":false,"given":"Mateusz","family":"Staciwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Duraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewelina","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3659-8115","authenticated-orcid":false,"given":"Marlena","family":"Broncel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Gorzelak-Pabis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.advms.2023.05.001_bib1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/joim.12406","article-title":"Inflammation and plaque vulnerability","volume":"278","author":"Hansson","year":"2015","journal-title":"J\u00a0Intern Med"},{"issue":"8","key":"10.1016\/j.advms.2023.05.001_bib2","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/ATVBAHA.119.311998","article-title":"Anticytokine immune therapy and atherothrombotic cardiovascular risk","volume":"39","author":"Ait-Oufella","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.advms.2023.05.001_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.advms.2023.05.001_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.it.2016.03.007","article-title":"IL-33 in T Cell differentiation, function, and immune homeostasis","volume":"37","author":"Peine","year":"2016","journal-title":"Trends Immunol"},{"issue":"5","key":"10.1016\/j.advms.2023.05.001_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.advms.2023.05.001_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cca.2019.05.023","article-title":"ST2 and the ST2\/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans","volume":"495","author":"Pusceddu","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10.1016\/j.advms.2023.05.001_bib7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/cvr\/cvq104","article-title":"Primary sources and immunological prerequisites for sST2 secretion in humans","volume":"87","author":"Mildner","year":"2010","journal-title":"Cardiovasc Res"},{"issue":"11","key":"10.1016\/j.advms.2023.05.001_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259026","article-title":"Role of the IL-33\/ST2 axis in cardiovascular disease: a systematic review and meta-analysis","volume":"16","author":"Sun","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.advms.2023.05.001_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20071868","article-title":"IL-33 reduces the development of atherosclerosis","volume":"205","author":"Miller","year":"2008","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.advms.2023.05.001_bib10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cyto.2019.05.010","article-title":"IL-33\/IL-33R in various types of carotid artery atherosclerotic lesions","volume":"120","author":"Stankovic","year":"2019","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.advms.2023.05.001_bib11","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American college of Cardiology\/American heart association task force on clinical practice guidelines and the heart failure society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.advms.2023.05.001_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2017","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.advms.2023.05.001_bib13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.advms.2023.05.001_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","article-title":"Recommendations for chamber quantification","volume":"7","author":"Lang","year":"2006","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.advms.2023.05.001_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pharmthera.2018.01.001","article-title":"Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities","volume":"186","author":"Ong","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.advms.2023.05.001_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinbiochem.2021.09.001","article-title":"Differences in biomarker concentrations and predictions of long-term outcome in patients with ST-elevation and non-ST-elevation myocardial infarction","volume":"98","author":"Hjort","year":"2021","journal-title":"Clin Biochem"},{"issue":"12","key":"10.1016\/j.advms.2023.05.001_bib17","first-page":"5588","article-title":"Comparison of long-term mortality of acute ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome patients after percutaneous coronary intervention","volume":"7","author":"Ren","year":"2014","journal-title":"Int J Clin Exp Med"},{"issue":"2","key":"10.1016\/j.advms.2023.05.001_bib18","article-title":"Comparison of short- and long-term prognosis between ST-elevation and non-ST-elevation myocardial infarction","volume":"10","author":"Bouisset","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"10.1016\/j.advms.2023.05.001_bib19","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.ijcard.2012.05.073","article-title":"Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers?","volume":"167","author":"Dhillon","year":"2013","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.advms.2023.05.001_bib20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ahj.2011.03.025","article-title":"Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with global registry of acute coronary events risk scoring and NT-proBNP","volume":"161","author":"Dhillon","year":"2011","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.advms.2023.05.001_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cyto.2014.02.014","article-title":"An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis","volume":"67","author":"Demyanets","year":"2014","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.advms.2023.05.001_bib22","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3892\/mmr.2014.2051","article-title":"IL-33 attenuates cardiac remodeling following myocardial infarction via inhibition of the p38 MAPK and NF-\u03baB pathways","volume":"9","author":"Yin","year":"2014","journal-title":"Mol Med Rep"},{"issue":"7","key":"10.1016\/j.advms.2023.05.001_bib23","first-page":"8247","article-title":"Expression and significance of inflammatory reactions mediated by the IL-33\/ST2 signaling pathway in the serum of heart failure patients","volume":"13","author":"Xiang","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.advms.2023.05.001_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1479-5876-10-120","article-title":"Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress","volume":"10","author":"Zhang","year":"2012","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.advms.2023.05.001_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3048941","article-title":"The utility of point of care test for soluble ST2 in predicting adverse cardiac events during acute care of ST-segment elevation myocardial infarction","volume":"2018","author":"Hartopo","year":"2018","journal-title":"Cardiol Res Pract"},{"issue":"15","key":"10.1016\/j.advms.2023.05.001_bib26","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/CIRCULATIONAHA.107.728022","article-title":"Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction","volume":"117","author":"Sabatine","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.advms.2023.05.001_bib27","article-title":"Multimarker risk stratification in patients with acute myocardial infarction","volume":"5","author":"O'Donoghue","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.advms.2023.05.001_bib28","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ahj.2010.02.022","article-title":"ST2 and mortality in non\u2013ST-segment elevation acute coronary syndrome","volume":"159","author":"Eggers","year":"2010","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.advms.2023.05.001_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095055","article-title":"Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome","volume":"9","author":"Demyanets","year":"2014","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.advms.2023.05.001_bib30","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1161\/01.CIR.0000038705.69871.D9","article-title":"Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction","volume":"106","author":"Weinberg","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.advms.2023.05.001_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijcard.2018.02.058","article-title":"ST2 as a predictor of late ventricular remodeling after myocardial infarction","volume":"259","author":"Bi\u00e8re","year":"2018","journal-title":"Int J Cardiol"},{"issue":"18","key":"10.1016\/j.advms.2023.05.001_bib32","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1161\/01.CIR.0000127958.21003.5A","article-title":"Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction","volume":"109","author":"Shimpo","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.advms.2023.05.001_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2009.08.047","article-title":"Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction","volume":"55","author":"Weir","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.advms.2023.05.001_bib34","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1136\/heartjnl-2014-305968","article-title":"ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality","volume":"100","author":"Hughes","year":"2014","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.advms.2023.05.001_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178939","article-title":"IL-33 and ST2 levels in chronic kidney disease: associations with inflammation, vascular abnormalities, cardiovascular events, and survival","volume":"12","author":"Gungor","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.advms.2023.05.001_bib36","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1681\/ASN.2010091011","article-title":"IL-33 exacerbates acute kidney injury","volume":"22","author":"Akcay","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.advms.2023.05.001_bib37","first-page":"8008","article-title":"Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressed Th2 cytokine profile in patients with diabetic nephropathy (CURES-134)","volume":"7","author":"Anand","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.advms.2023.05.001_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2172-15-19","article-title":"IL-33 is negatively associated with the BMI and confers a protective lipid\/metabolic profile in non-diabetic but not diabetic subjects","volume":"15","author":"Hasan","year":"2014","journal-title":"BMC Immunol"},{"issue":"10","key":"10.1016\/j.advms.2023.05.001_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047830","article-title":"Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes?","volume":"7","author":"Miller","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.advms.2023.05.001_bib40","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/eci.12785","article-title":"Multibiomarker analysis in patients with acute myocardial infarction","volume":"47","author":"Schernthaner","year":"2017","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"10.1016\/j.advms.2023.05.001_bib41","volume":"11","author":"O'Meara","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.advms.2023.05.001_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/14017431.2019.1583363","article-title":"ST2 in heart failure with preserved and reduced ejection fraction","volume":"53","author":"Najjar","year":"2019","journal-title":"Scand Cardiovasc J"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112623000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112623000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:43:28Z","timestamp":1761824608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112623000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1896112623000160"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2023.05.001","relation":{},"ISSN":["1896-1126"],"issn-type":[{"type":"print","value":"1896-1126"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-33\/sST2: Dynamic assessment in patients with acute coronary syndrome","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2023.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}